TRPC6 and focal segmental glomerulosclerosis: Although there are currently no selective TRPC6 antagonists in clinical trials, three drug classes commonly used for the treatment of FSGS [121] regulate TRPC6 expression, including angiotensin-converting enzyme inhibitors (ACEIs), angiotensin II receptor blockers (ARBs), and calcineurin inhibitors (CNIs) [61,74,77].